How Much Will Selinexor Cost in 2023?

Selinexor (Selinexor), together with dexamethasone, is used to treat multiple myeloma (a type of bone marrow cancer) that has come back or has not responded to at least4 other treatments. Selinisol is also used with bortezomib and dexamethasone to treat multiple myeloma in patients who have been previously treated with at least one other drug. It is also used to treat certain types of diffuse large B-cell lymphoma (DLBCL), a cancer that starts in white blood cells, in adult patients whose cancer has come back or has not responded to at least two other treatments.

Selinisol is a drug called a selective inhibitor of nuclear export (SINE), which works by killing cancer cells. Seleniso is a small molecule inhibitor of nuclear export protein -1 (XPO1) , which blocks the transport of tumor suppressor proteins, oncoproteins and growth regulatory factors such as c-myc and cyclin D1 from the nucleus to the cytoplasm. This leads to cell cycle arrest and apoptosis in cancer cells but not non-cancer cells. Selinisol therapy was found to extend progression-free survival in patients with highly pretreated advanced, relapsed or refractory multiple myeloma.

The original drug Seleniso has been launched in China, but it has not yet entered the scope of medical insurance. The price of 20mg*12 tablets per box may be around 20,000 yuan, and the price of 20mg*16 tablets per box may be around 30,000 yuan. The US version of the original Seleniso drug sold overseas, with a specification of 20mg*8 tablets, may cost more than 100,000 yuan per box (the price may fluctuate due to exchange rates), which is very expensive. At present, there are also generic Seleniso drugs produced and marketed overseas, and the price is relatively cheap. For example, the price of 20mg*16 tablets per box produced by a Laos pharmaceutical factory may be around 4,000 yuan (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the original drugs sold domestically and abroad.